Kronos Bio, Inc.

13 patents currently held · Updated Nov 14, 2026

11 more in force are now held by other companies

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Ending by 2030

Dec 2029

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Mar 1, 2027
The maintenance fee for 6-(1H-indazol-6-YL)-N-(4-morpholinophenyl)imidazo[1,4-A]pyrazin-8-amine for treating leukemia or lymphoma (US 9,120,811) comes due Mar 1, 2027. Unpaid by Sep 1, 2027, it lapses early.
2 fees due Jun 15 to 19, 2027 · next Jun 15

Which patents, and when each one lapses · Pro

Recent changes

2 terms have ended since Aug 16, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Patent	Title	Status	Expires	Confidence
US 8,450,321	6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor In force Ends no later than Dec 7, 2029 · From the USPTO record	In force	Ends no later than Dec 7, 2029	From the USPTO record
US 8,455,493	Imidazopyrazine Syk Inhibitors In force Term ends Dec 7, 2029 · High confidence	In force	Term ends Dec 7, 2029	High confidence
US 8,962,835	Imidazopyrazine Syk Inhibitors In force Term ends Dec 7, 2029 · Medium confidence	In force	Term ends Dec 7, 2029	Medium confidence
US 9,120,811	6-(1H-indazol-6-YL)-N-(4-morpholinophenyl)imidazo[1,4-A]pyrazin-8-amine for treating leukemia or lymphoma In force Ends no later than Dec 7, 2029 · From the USPTO record	In force	Ends no later than Dec 7, 2029	From the USPTO record
US 9,212,191	6-(2,3-Dihydro-1H-PYRIDO-[2,3-b][1,4]OXAZIN-7-YL)-N-(4-Morpholinophenyl)IMIDAZO[1,2-a]PYRAZIN-8-Amine AS A SPLEEN TYROSINE KINASE INHIBITOR In force Term ends Dec 7, 2029 · High confidence	In force	Term ends Dec 7, 2029	High confidence
US 9,796,718	6-(BENZO[d]THIAZOL-5-YL)-N-(3,4-Dimethoxyphenyl)IMIDAZO[1,2-a]PYRAZIN-8-Amine In force Term ends Jan 6, 2030 · High confidence	In force	Term ends Jan 6, 2030	High confidence
US 10,092,583	Imidazopyridines Syk inhibitors In force Term ends Mar 11, 2031 · From the USPTO record	In force	Term ends Mar 11, 2031	From the USPTO record
US 9,382,256	Formulation of Syk inhibitors In force Ends no later than Jul 29, 2034 · From the USPTO record	In force	Ends no later than Jul 29, 2034	From the USPTO record
US 9,657,023	Polymorph of Syk inhibitors In force Ends no later than Jul 29, 2034 · From the USPTO record	In force	Ends no later than Jul 29, 2034	From the USPTO record
US 9,918,939	Formulation of Syk inhibitors In force Ends no later than Jul 29, 2034 · From the USPTO record	In force	Ends no later than Jul 29, 2034	From the USPTO record

10 of 13 patents shown.

Pro members see all 13.

Pro members: see all 13 patents

Also on record, not counted in the 13: 11 patents in force now held by others · 18 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

1 pending · 1 abandoned · 2 no status recorded

List them